Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]
In development
Reference number: GID-TA11220
Expected publication date: TBC
NICE has received 1 appeal, that falls within one or more of the two strictly limited grounds for appeal, against the Final Draft Guidance on the above technology from the following organisation:
Eisai Europe Limited
The appeal panel will convene on TBC via Zoom to hear oral representations from the appellant.